Tesamorelin
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- FDA-approved
What it is
A stabilized GHRH analog, FDA-approved to reduce visceral fat in HIV lipodystrophy, used off-label for fat loss, lipid gains, and GH restoration. Evidence is strong for those effects, muscle gains are modest, and cognitive benefit is only weakly supported. Injections often cause site reactions and joint aches, effects reverse once stopped, and a theoretical cancer risk from IGF-1 is unresolved. FDA-approved, though longevity use is off-label.
Read Full recordStudied uses & evidence
Studied uses(8)
Visceral fat reduction
HighFDA-approved indication, confirmed in two large phase 3 RCTs in HIV lipodystrophy.
Lipid improvement
HighSignificant triglyceride and cholesterol ratio improvements in RCTs, though LDL unchanged.
Liver fat/NAFLD
HighReduced liver fat and fibrosis progression in a 12-month RCT, limited to HIV cohorts.
Evidence limits
- Evidence Level
- Level 1 — FDA Approved
Two pivotal Phase III RCTs (n=806 combined) led to FDA approval 2010. Additional RCTs for NAFLD, muscle composition, cognition. 2026 meta-analysis of 5 RCTs confirmed efficacy. Long-term data to 52 weeks.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active malignancy
AbsoluteFDA label: discontinue if active malignancy develops. GH promotes tumor growth.
Disruption of hypothalamic-pituitary axis from surgery/radiation
HighMay not work if pituitary is damaged — requires functional somatotrophs.
Diabetic retinopathy
HighGH elevation can worsen proliferative retinopathy.
General cautions
Pregnancy
AbsoluteFDA label: can cause fetal harm based on mechanism of action.
Risk summary(7)
Risks = level of concern: High · Moderate · Low · Theoretical
Injection site reactions (most common)
HighArthralgia, pain in extremities, peripheral edema, myalgia
Moderate50% develop anti-tesamorelin antibodies (no apparent efficacy impact)
LowIncreased risk of developing diabetes: HbA1c reached at least 6.5% in 5% versus 1% on placebo.
ModerateEffects reverse upon cessation — requires ongoing treatment
HighTheoretical cancer risk with long-term GH/IGF-1 elevation
TheoreticalContraindicated: pregnancy, active malignancy, disrupted hypothalamic-pituitary axis
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Prescribing labels in Full record
- Monitoring & labs in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.